ENDRA Life Sciences Inc (NDRA)

ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement FinancingJune 25, 2026 9:51 AM
Business Wire Combination, if successful, would establish Noble Africa as a Nasdaq-listed, helium platform for Renergen’s Virginia Gas Project Listing expected to provide investors with direct exposure to one of the few publicly traded helium development assets globally, at a time of tightening supply Concurrent private placement expected to generate approximately $50 million in gross proceeds to support project development ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes," “ASPI” or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or “NDRA”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that ASP Isotopes’ wholly-owned subsidiary, Noble Africa LLC (“Noble Africa”), an intermediate holding company for Renergen Limited (“Renergen”), will merge with a subsidiary of ENDRA, with Noble Africa continuing as the surviving entity (the “Proposed Merger” and, together with the related transactions, the “Proposed Transactions”). Upon completion of the Proposed Transactions, the combined company plans to operate under the name Noble Africa Inc. and will apply to trade on The Nasdaq Stock Market LLC (“Nasdaq”) under the ticker symbol “NOBA.” In connection with the Proposed Transactions, Noble Africa has entered into subscription agreements with certain accredited investors, qualified institutional buyers and non U.S.-persons securing commitments for a private placement into Noble Africa that is expected to result in total gross proceeds of approximately $50 million, including approximately $20 million from ASP Isotopes, as the lead investor, and approximately $30 million from other investors, including $750,000 from certain directors and management of ASP Isotopes. The private placement financing is expected to close immediately prior to completion of the Proposed Merger. “We believe this transaction represents an important step in positioning Renergen’s Virginia Gas Project as a dedicated, publicly traded platform at a time when secure, reliable helium supply is increasingly important to critical industries,” said Paul Mann, Chief Executive Officer and Executive Chairman of ASP Isotopes. “The Proposed Merger and concurrent financing are expected to provide Noble Africa with the capital structure, public market access and funding needed to advance Phase 1 and Phase 2 development, while allowing ASP Isotopes stockholders to retain meaningful exposure to the long-term opportunity.” “The combination of ENDRA with Noble Africa represents an exciting new chapter for our stockholders. We’ve been impressed with the ASP Isotopes team ever since our initial meetings, and think that the Virginia Gas Project represents a well-positioned opportunity in a dynamic industry,” said Alex Tokman, Chief Executive Officer of ENDRA. About the Proposed Transactions Under the terms of the merger agreement, as of the closing of the Proposed Transactions, ASP Isotopes is expected to own approximately 89% of the combined company, the pre-closing ENDRA stockholders are expected to own approximately 3% of the combined company, and investors in the private placement financing (other than ASPI) are expected to own approximately 7% of the combined company. The Proposed Transactions have received approvals by the Board of Directors of both ASP Isotopes and ENDRA and are expected to close in the third or fourth quarter of 2026, subject to the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission (the “SEC”) to register the securities to be issued in connection with the Proposed Transactions, approval by the stockholders of ENDRA and the satisfaction of other customary closing conditions. The combined company plans to operate under the name Noble Africa Inc. and will initially be led by Paul E. Mann, Chief Executive Officer of Renergen and Chief Executive Officer and Executive Chairman of ASP Isotopes, and Nick Mitchell, Chief Operating Officer of Renergen and Co-Chief Operating Officer of ASP Isotopes. The combined company’s Board of Directors will consist of six directors selected by ASP Isotopes, including the Chief Executive Officer of the combined company, four non-executive directors designated by ASP Isotopes and one non-executive director designated by ENDRA. Advisors Lucid Capital Markets is serving as financial advisor, and K&L Gates LLP is serving as legal counsel, to ENDRA. Haynes and Boone, LLP is serving as legal counsel to ASP Isotopes. Lucid Capital Markets (U.S. investors) and OceanWall (ex-U.S. investors) are acting as placement agents in connection with the concurrent private placement financing. Ellenoff Grossman & Schole LLP is serving as legal counsel to the placement agents. About ASP Isotopes Inc. ASP Isotopes is developing a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy. ASP Isotopes’ proprietary technologies, the Aerodynamic Separation Process (“ASP technology”) and Quantum Enrichment (“QE technology”), are designed to enable the production of isotopes for a range of industrial and advanced technology applications. ASP Isotopes operates isotope enrichment facilities in Pretoria, South Africa, focused on the enrichment of low atomic mass elements, or light isotopes. For more information, please visit www.aspisotopes.com. About Renergen Renergen Limited, a subsidiary of ASP Isotopes Inc., is a company incorporated under the laws of the Republic of South Africa whose principal asset is its 94.5% equity ownership in Tetra4 Proprietary Limited. Tetra4 Proprietary Limited holds an onshore petroleum production right and engages in the production and liquefaction of natural gas and the exploration and development of helium resources at the Virginia Gas Plant located in Free State Province, South Africa. About ENDRA Life Sciences Inc. ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS ® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Important Additional Information and Where to Find It This communication relates to the Proposed Transactions involving ENDRA, ASP Isotopes Renergen and Noble Africa and may be deemed to be solicitation material in respect of the Proposed Transactions. In connection with the Proposed Transactions, ENDRA intends to file relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that will contain a proxy statement (the “Proxy Statement”) and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement or for any other document that ENDRA may file with the SEC and/or send to its stockholders in connection with the Proposed Transactions. INVESTORS AND STOCKHOLDERS OF ENDRA ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ENDRA, ASP ISOTOPES, RENERGEN, NOBLE AFRICA, THE PROPOSED TRANSACTIONS AND RELATED MATTERS. Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by ENDRA and ASP Isotopes with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. ENDRA’S Internet website address is www.endrainc.com. ENDRA’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge through the investor relations page of its Internet website as soon as reasonably practicable after it electronically files such material with, or furnishes such material to, the SEC. Participants in the Solicitation ENDRA, ASP Isotopes, Renergen, Noble Africa, and their respective directors and managers and certain of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies from ENDRA’s stockholders in connection with the Proposed Transactions under the rules of the SEC. Information about ENDRA’s directors and executive officers, including a description of their interests in ENDRA, is included in ENDRA’s most recent Annual Report on Form 10-K for the year ended December 31, 2025. Information about ASP Isotopes’ directors and executive officers, including a description of their interests in ASP Isotopes, is included in ASP Isotopes’ most recent Annual Report on Form 10-K for the year ended December 31, 2025. Additional information regarding the persons who may be deemed participants in the proxy solicitations, including the directors and executive officers of Renergen, and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above. No Offer or Solicitation This press release is not intended to and does not constitute a solicitation of a proxy, consent or approval with respect to any securities or in respect of the Proposed Transactions or an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction. Cautionary Statement Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements can be identified by words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends, ” “may,” “might,” “plans,” “projects,” “will,” and words of a similar nature. Examples of forward-looking statements include, but are not limited to, statements relating to the Proposed Transactions; the expected structure, timing and the completion of the Proposed Merger, the Proposed Transactions and the expected effects, perceived benefits or opportunities of the Proposed Transactions; the combined company’s listing on Nasdaq after the closing of the Proposed Transactions; expectations regarding the structure, timing and completion of the Proposed Transactions, including investment amounts from investors, timing of closing of the Proposed Transactions, expected proceeds, expectations regarding the use of proceeds, and impact on ownership structure; the anticipated timing of the closing of the Proposed Transaction; the expected executive officers and directors of the combined company; each company’s and the combined company’s expected cash position at the closing of the Proposed Transactions and cash runway of the combined company following the Proposed Transactions; the future operations and pipeline, estimates of financial position, competitive landscape, addressable market and strategic and financial initiatives of the combined company; the nature, strategy and focus of the combined company; statements regarding the continuation of Renergen’s Virginia Gas Project and its funding timeline and other statements that are not historical fact. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause actual results and financial condition to differ materially from those indicated in the forward-looking statements, including, but not limited to: the outcomes of various strategies and projects undertaken by Renergen; the potential impact of laws or government regulations or policies in South Africa or elsewhere; Renergen’s future capital requirements and sources and uses of cash; Renergen’s ability to obtain funding for its operations and future growth, including debt funding for Phase 2 of the Virginia Gas Project; Renergen’s reliance on the efforts of third parties; Renergen’s ability to complete Phase 1 and 2 of the Virginia Gas Project; the financial terms of any current and future commercial arrangements; Renergen’s ability to complete certain transactions and realize anticipated benefits from acquisitions and contracts; Renergen’s ability to comply with the terms of the loan and credit facilities of Renergen's subsidiary Tetra4; the ability of Renergen and its subsidiaries to retain and hire key personnel; the volatility of LNG and liquid helium prices; Renergen's success in discovering, estimating and developing natural gas and helium reserves; actions of competitors or regulators; limitations in the availability of, and costs of, supplies, materials, contractors and services that may delay the drilling or completion of wells or make such wells more expensive; the amount and timing of future development costs; uncertainties inherent in estimating quantities of natural gas and helium reserves and projecting future rates of production and timing of development activities; risks relating to the lack of capital available on acceptable terms to finance the Renergen's continued growth; the competitive nature of Renergen’s industry; the risk that the conditions to the closing or consummation of the Proposed Transactions are not satisfied, including the failure to timely obtain approval of the Proposed Merger from ENDRA stockholders, if at all; the risk that the proposed financings are not completed in a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed Transactions and the ability of each of ENDRA and Noble Africa to consummate the Proposed Transactions; risks related to ENDRA’s continued listing on Nasdaq until closing of the Proposed Transactions and the combined company’s ability to remain listed following the closing of the Proposed Transactions; the ability to obtain debt financing on terms that are favorable, or at all; the risk that Renergen does not receive funding from the U.S. DFC or Standard Bank SA or that such funding is delayed; risks related to ENDRA’s ability to correctly estimate its respective operating expenses and its respective expenses associated with the Proposed Transactions, as applicable, pending the closing of the Proposed Transactions, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of ENDRA, and other events and unanticipated spending and costs that could reduce ENDRA’s cash resources; risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Proposed Transactions; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the Proposed Merger on ENDRA’s or Renergen’s business relationships, operating results and business generally; costs related to the Proposed Merger; risks related to the market price of ENDRA’s common stock relative to the value suggested by the Proposed Merger; the outcome of any legal proceedings that may be instituted against ENDRA, Noble or any of their respective directors, managers, or officers related to the Proposed Transactions; costs of the Proposed Transactions and unexpected costs, charges or expenses resulting from the Proposed Transactions; changes in regulatory requirements and government incentives; risks associated with the possible failure to realize, or that it may take longer to realize than expected, certain anticipated benefits of the Proposed Transactions, including with respect to future financial and operating results, legislative, regulatory, political and economic developments, and those uncertainties and factors; and the risk of involvement in litigation, including securities class action litigation, that could divert the attention of the management of ENDRA or the combined company, harm the combined company’s business and may not be sufficient for insurance coverage to cover all costs and damages, and the other risks and uncertainties described in ENDRA’s SEC reports, and under the heading “Risk Factors” in its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, the factors disclosed in Part I, Item 1A. “Risk Factors” of ASP Isotopes’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (as amended) and in ASP Isotopes’ subsequent reports filed with the SEC, each of which are available at www.sec.gov, and in other filings that ENDRA and ASP Isotopes have made and will make with the SEC in connection with the Proposed Transactions, including the Form S-4 and Proxy Statement described above under “Additional Information and Where to Find It”. Any forward-looking statement made by the parties in this press release is based only on information currently available to the parties and speaks only as of the date on which it is made. The parties undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. No information in this press release should be interpreted as an indication of future success, revenues, results of operations, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon. View source version on businesswire.com: https://www.businesswire.com/news/home/20260625997522/en/ Company Contact:
Investor Relations
investors@endrainc.com
www.endrainc.com Investor Relations Contact:
Vivian Cervantes
Alliance Advisors IR
973-873-7724
vcervantes@allianceadvisors.com Original: ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing

$NDRA ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

https://www.businesswire.com/news/home/20260518282190/en/ENDRA-Life-Sciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update.

Business Update

Initiated Evaluation of Strategic Alternatives
On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value.
ENDRA will continue to execute on its strategic and operating initiatives during the review process, and has not set a timetable for completion of the process.
Demonstrated Strong Clinical Progress with TAEUS® Liver
On May 14, 2026, the Company announced multi-site clinical validation results for its TAEUS® Liver device demonstrating strong agreement with MRI-PDFF, high reproducibility and consistent performance across operators, sites and patient populations. The analysis, which included 64 patients across U.S. and Canadian sites, reported a correlation to MRI-PDFF of r=0.90, diagnostic accuracy with Area Under the Receiver Operating Characteristic (AUROC) values ranging from 0.95-0.99 at key thresholds, reproducibility with an Intraclass Correlation Coefficient (ICC) of 0.89 and no meaningful dependence on body mass index (BMI) or body habitus.
On February 26, 2026, ENDRA reported favorable results from a new study that demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of SLD, which now affects approximately 30% of adults worldwide. The study involved 14 subjects and a total of 56 unique measurements, with TAEUS achieving an ICC of 0.89 with standard error of measurement of 3.3% using independent operators.
These data support TAEUS’s objective to deliver a standardized, accurate and repeatable liver fat test for the growing population affected by SLD. TAEUS Liver has the potential to be deployed in routine clinical practice to address large, underserved populations and could potentially be utilized by pharmaceutical companies for patient recruitment and follow-up in clinical trials.

Management Commentary

“During the first quarter, we continued to strengthen the clinical foundation for TAEUS Liver while maintaining disciplined operational execution,” said Alexander Tokman, CEO of ENDRA Life Sciences. “The recently announced multi-site validation data demonstrated strong agreement with MRI-PDFF across operators and patient populations. These data reinforce our belief that TAEUS Liver has the potential to deliver a practical, point-of-care solution for the large and growing population affected by steatotic liver disease. We remain focused on advancing our regulatory and commercialization strategy while managing our resources carefully.”

First Quarter 2026 Financial Results

In the first quarter of 2026, cash used in operations decreased to $1.1 million from $1.3 million in the same period of 2025.

Total operating expenses for the first quarter of 2026 were $2.2 million compared with $1.5 million in the prior-year period. The increase included an increase in non-cash stock-compensation expense of $491,000 and an increase of $302,000 in long-term prepaid expenses associated with clinical learnings related to the TAEUS Liver device. As a result, the net loss in the first quarter of 2026 was $1.3 million compared to $1.0 million in the same quarter last year.

As of March 31, 2026, ENDRA had approximately $356,000 in cash and cash equivalents and held approximately $2.4 million in its Digital Asset Treasury, representing an additional component of its capital management strategy.

$NDRA ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility

https://www.businesswire.com/news/home/20260514255247/en/ENDRA-Life-Sciences-Reports-Multi-Site-Validation-of-TAEUS-Liver-Device-Demonstrating-MRI-like-Accuracy-and-Reproducibility

Results confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting planned regulatory pathway

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS® Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites.

The analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independent operators and patient populations. TAEUS Liver’s thermoacoustic fat fraction measurement closely tracked MRI-PDFF results for patients along the full spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD) and those with elevated body mass index (BMI).

Key results in the analysis included:

Correlation to MRI-PDFF: r=0.90 (combined cohort)
Diagnostic accuracy: AUROC 0.95–0.99 at key thresholds
Mean error: ~3%, consistent across sites
Reproducibility: ICC=0.89 across operators
~90% of measurements within ~5% of MRI values
No dependence on BMI or body habitus

“The multi-site data aggregation shows that TAEUS Liver delivers MRI-like liver fat quantification at the point of patient care, with a strong correlation to MRI-PDFF of 0.90 and no meaningful bias. We believe the combination of this performance coupled with TAEUS Liver’s portability and low cost could make routine liver fat assessment feasible for the more than two billion people worldwide living with MASLD,” said Alexander Tokman, Chief Executive Officer of ENDRA Life Sciences.

TAEUS Liver is designed to provide MRI-aligned performance in a portable, point-of-care format with an anticipated per-scan cost of under $200, which is less than 8% of a typical MRI-PDFF exam. By enabling frequent, affordable assessments, TAEUS Liver could support routine monitoring of treatment-driven changes in liver fat that are difficult to track with MRI alone. The TAEUS system's performance contrasts sharply with ultrasound techniques, which experience high inter-observer variability and subjective interpretations.

These study results support TAEUS Liver’s objective to deliver a standardized, accurate and repeatable liver fat test for the growing population affected by MASLD. TAEUS Liver could be deployed in routine clinical practice to address large, underserved populations and could potentially be utilized by pharmaceutical companies for patient recruitment and follow-up in clinical trials. As new metabolic therapies enter the market, the ability to detect small, incremental changes in liver fat without the cost burden of repeated MRI scans becomes increasingly important. ENDRA’s innovative approach with TAEUS combines the precision traditionally associated with expensive imaging modalities with the practical deployment advantages of ultrasound-based systems.

ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and ReproducibilityMay 14, 2026 8:00 AM
Business Wire Results confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting planned regulatory pathway ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS® Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. The analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independent operators and patient populations. TAEUS Liver’s thermoacoustic fat fraction measurement closely tracked MRI-PDFF results for patients along the full spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD) and those with elevated body mass index (BMI). Key results in the analysis included: Correlation to MRI-PDFF: r=0.90 (combined cohort) Diagnostic accuracy: AUROC 0.95–0.99 at key thresholds Mean error: ~3%, consistent across sites Reproducibility: ICC=0.89 across operators ~90% of measurements within ~5% of MRI values No dependence on BMI or body habitus “The multi-site data aggregation shows that TAEUS Liver delivers MRI-like liver fat quantification at the point of patient care, with a strong correlation to MRI-PDFF of 0.90 and no meaningful bias. We believe the combination of this performance coupled with TAEUS Liver’s portability and low cost could make routine liver fat assessment feasible for the more than two billion people worldwide living with MASLD,” said Alexander Tokman, Chief Executive Officer of ENDRA Life Sciences. TAEUS Liver is designed to provide MRI-aligned performance in a portable, point-of-care format with an anticipated per-scan cost of under $200, which is less than 8% of a typical MRI-PDFF exam. By enabling frequent, affordable assessments, TAEUS Liver could support routine monitoring of treatment-driven changes in liver fat that are difficult to track with MRI alone. The TAEUS system's performance contrasts sharply with ultrasound techniques, which experience high inter-observer variability and subjective interpretations. These study results support TAEUS Liver’s objective to deliver a standardized, accurate and repeatable liver fat test for the growing population affected by MASLD. TAEUS Liver could be deployed in routine clinical practice to address large, underserved populations and could potentially be utilized by pharmaceutical companies for patient recruitment and follow-up in clinical trials. As new metabolic therapies enter the market, the ability to detect small, incremental changes in liver fat without the cost burden of repeated MRI scans becomes increasingly important. ENDRA’s innovative approach with TAEUS combines the precision traditionally associated with expensive imaging modalities with the practical deployment advantages of ultrasound-based systems. About ENDRA Life Sciences Inc. ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section of our website, www.endrainc.com. Forward-Looking Statements All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements—based on certain assumptions and describing our future plans, strategies, and expectations—can generally be identified by the use of terms such as “approximate,” “anticipate,” “attempt,” “believe,” “can,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “hope,” “intend,” “may,” “plan,” “possible,” “potential,” “project,” “seek,” “should,” “will,” “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are express differently. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: expectations regarding our treasury strategy and our ability to execute it successfully; our limited commercial experience, limited cash resources, and history of losses; our ability to obtain adequate financing to fund operations in the future; our ability to regain and maintain compliance with Nasdaq listing standards; delays or changes in regulatory requirements, policies, or guidelines; the repeatability of clinical results across larger trial populations; potential delays in submitting required regulatory applications or other submissions to, or receiving approvals from, the U.S. Food and Drug Administration (“FDA”) or other regulatory agencies; our ability to obtain and maintain required CE mark certifications and secured required FDA and other governmental approvals for our Thermo Acoustic Enhanced Ultrasound (“TAEUS®”) applications; our ability to develop commercially viable products based on our TAEUS® technology; market acceptance of our technology; the effect of macroeconomic conditions on our business; results of studies, which may be negative or inconclusive; our ability to secure and maintain development partners; reliance on third parties, collaborations, strategic alliances, and licensing arrangements; the competitive landscape in the healthcare industry; our ability to protect our intellectual property; changes in healthcare industry practices or reimbursement policies; our ability to comply with regulations from federal, state, local, and foreign governmental agencies; risks related to shifts in regulatory, accounting, or tax treatment affecting our treasury activities; the potential impact of any changes in financial reporting requirements; the risk that our stock price may be affected by the performance or valuation of assets held in our treasury; a determination that we are an investment company under the Investment Company Act of 1940; our ability to achieve profitability; our dependence on key members of management; and other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely on forward-looking statements as predictions of future events. Forward-looking statements in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update such statements to reflect actual results or changes in expectations, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260514255247/en/ Company Contact:
Investor Relations
investors@endrainc.com
www.endrainc.com Investor Relations Contact:
Yvonne Briggs
Alliance Advisors IR
(310) 691-7100
ybriggs@allianceadvisors.com Original: ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility

$NDRA ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

https://www.businesswire.com/news/home/20260331142790/en/ENDRA-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter and year ended December 31, 2025, and provided a business update.

Business Update

Initiated Evaluation of Strategic Alternatives
On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic alternatives to maximize shareholder value.
The Company intends to continue executing on its strategic and operating initiatives during the review process, and has not set a timetable for completion of the process.
Demonstrated Strong Clinical Progress with TAEUS® Liver
On November 20, 2025, ENDRA announced positive results from its feasibility study that demonstrated the ability of TAEUS Liver, as redesigned in 2025, to accurately quantify liver fat fraction – a key MASLD/MASH biomarker – with a Pearson correlation coefficient of r=0.89 across the full stages of steatotic disease and BMIs.
On December 4, 2025, the Company announced additional feasibility results that demonstrated TAEUS Liver’s strong concordance with MRI-PDFF, the industry’s gold standard for non-invasive liver fat assessment, at critical liver fat fraction thresholds of 12-17% and 20-22%, thereby positioning the device as a clinical SLD tool for future use in pharmaceutical trials.
On February 26, 2026, the Company reported favorable results from a new study that demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of SLD, which now affects approximately 30% of adults worldwide. TAEUS achieved an Intraclass Correlation Coefficient of 0.89 with standard error of measurement of 3.3% using independent operators.
These data support TAEUS’s objective to deliver a standardized, accurate and repeatable liver fat test for the growing population affected by SLD. TAEUS Liver has the potential to be deployed in routine clinical practice to address large, underserved populations and could potentially be utilized by pharmaceutical companies for patient recruitment and follow-up in clinical trials.

“Over the past year we significantly strengthened the clinical foundation for TAEUS, demonstrating performance that we believe positions our technology alongside the current standard of care, while maintaining the accessibility, scalability and cost of handheld ultrasound systems,” said Alexander Tokman, ENDRA’s Chief Executive Officer. “We remain highly confident in the long-term potential of TAEUS and are optimistic about the value it can deliver to patients, clinicians and our shareholders. As we evaluate strategic alternatives for the company, our focus is on ensuring that this progress translates into maximum benefit for all stakeholders.”

Fourth Quarter Financial Results

In the fourth quarter of 2025, cash used in operations increased to $1.6 million, compared with $1.5 million in the fourth quarter of 2024.

Operating expenses in the fourth quarter of 2025 decreased to $1.6 million, compared with $4.3 million in the same period last year. As a result, the net loss in the fourth quarter of 2025 was $3.2 million, compared with a net loss of $4.2 million in the fourth quarter of 2024.

2025 Financial Results

During 2025 the Company benefitted from actions taken throughout 2024 to streamline operations and focus resources on core development priorities, resulting in a significant decrease in operating expenses.

Operating expenses in 2025 decreased to $5.8 million, compared with $10.8 million in 2024, which included a $2.3 million non-cash inventory valuation charge reflecting the Company's strategic shift to align the TAEUS Liver device with larger market opportunities. The Company reported a net loss of $7.0 million in 2025, compared with a net loss of $11.5 million in 2024. The improvement was primarily driven by lower operating expenses, partially offset by continued investment in the advancement of the Company’s technology and clinical programs.

As of December 31, 2025, ENDRA had approximately $762,000 in cash and cash equivalents and held approximately $2.0 million in its Digital Asset Treasury, representing an additional component of its capital management strategy.

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 31, 2026 4:05 PM
Business Wire
ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter and year ended December 31, 2025, and provided a business update.


Business Update



Initiated Evaluation of Strategic Alternatives


On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic alternatives to maximize shareholder value.



The Company intends to continue executing on its strategic and operating initiatives during the review process, and has not set a timetable for completion of the process.






Demonstrated Strong Clinical Progress with TAEUS® Liver


On November 20, 2025, ENDRA announced positive results from its feasibility study that demonstrated the ability of TAEUS Liver, as redesigned in 2025, to accurately quantify liver fat fraction – a key MASLD/MASH biomarker – with a Pearson correlation coefficient of r=0.89 across the full stages of steatotic disease and BMIs.



On December 4, 2025, the Company announced additional feasibility results that demonstrated TAEUS Liver’s strong concordance with MRI-PDFF, the industry’s gold standard for non-invasive liver fat assessment, at critical liver fat fraction thresholds of 12-17% and 20-22%, thereby positioning the device as a clinical SLD tool for future use in pharmaceutical trials.



On February 26, 2026, the Company reported favorable results from a new study that demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of SLD, which now affects approximately 30% of adults worldwide. TAEUS achieved an Intraclass Correlation Coefficient of 0.89 with standard error of measurement of 3.3% using independent operators.



These data support TAEUS’s objective to deliver a standardized, accurate and repeatable liver fat test for the growing population affected by SLD. TAEUS Liver has the potential to be deployed in routine clinical practice to address large, underserved populations and could potentially be utilized by pharmaceutical companies for patient recruitment and follow-up in clinical trials.






“Over the past year we significantly strengthened the clinical foundation for TAEUS, demonstrating performance that we believe positions our technology alongside the current standard of care, while maintaining the accessibility, scalability and cost of handheld ultrasound systems,” said Alexander Tokman, ENDRA’s Chief Executive Officer. “We remain highly confident in the long-term potential of TAEUS and are optimistic about the value it can deliver to patients, clinicians and our shareholders. As we evaluate strategic alternatives for the company, our focus is on ensuring that this progress translates into maximum benefit for all stakeholders.”


Fourth Quarter Financial Results


In the fourth quarter of 2025, cash used in operations increased to $1.6 million, compared with $1.5 million in the fourth quarter of 2024.


Operating expenses in the fourth quarter of 2025 decreased to $1.6 million, compared with $4.3 million in the same period last year. As a result, the net loss in the fourth quarter of 2025 was $3.2 million, compared with a net loss of $4.2 million in the fourth quarter of 2024.


2025 Financial Results


During 2025 the Company benefitted from actions taken throughout 2024 to streamline operations and focus resources on core development priorities, resulting in a significant decrease in operating expenses.


Operating expenses in 2025 decreased to $5.8 million, compared with $10.8 million in 2024, which included a $2.3 million non-cash inventory valuation charge reflecting the Company's strategic shift to align the TAEUS Liver device with larger market opportunities. The Company reported a net loss of $7.0 million in 2025, compared with a net loss of $11.5 million in 2024. The improvement was primarily driven by lower operating expenses, partially offset by continued investment in the advancement of the Company’s technology and clinical programs.


As of December 31, 2025, ENDRA had approximately $762,000 in cash and cash equivalents and held approximately $2.0 million in its Digital Asset Treasury, representing an additional component of its capital management strategy.


About ENDRA Life Sciences Inc.


ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section of our website, www.endrainc.com.


Forward-Looking Statements


All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements—based on certain assumptions and describing our future plans, strategies, and expectations—can generally be identified by the use of terms such as “approximate,” “anticipate,” “attempt,” “believe,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “hope,” “intend,” “may,” “plan,” “possible,” “potential,” “project,” “seek,” “should,” “will,” “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are express differently. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.


Applicable risks and uncertainties include, among others: expectations regarding the strategic alternative review process and the chance that it may not result in any transaction or other strategic outcome; our limited commercial experience, limited cash resources, and history of losses; our ability to obtain adequate financing to fund operations in the future; risks related to shifts in regulatory, accounting, or tax treatment affecting our treasury activities; the potential impact of any changes in financial reporting requirements; the risk that our stock price may be affected by the performance or valuation of assets held in our treasury; a determination that we are an investment company under the Investment Company Act of 1940; our ability to achieve profitability; delays or changes in regulatory requirements, policies, or guidelines; potential delays in submitting required regulatory applications or other submissions to, or receiving approvals from, the U.S. Food and Drug Administration (“FDA”) or other regulatory agencies; our ability to obtain and maintain required CE mark certifications and secured required FDA and other governmental approvals for our Thermo Acoustic Enhanced Ultrasound (“TAEUS®”) applications; our ability to develop commercially viable products based on our TAEUS® technology; market acceptance of our technology; the effect of macroeconomic conditions on our business; results of studies, which may be negative or inconclusive; our ability to secure and maintain development partners; reliance on third parties, collaborations, strategic alliances, and licensing arrangements; the competitive landscape in the healthcare industry; our ability to protect our intellectual property; changes in healthcare industry practices or reimbursement policies; our ability to comply with regulations from federal, state, local, and foreign governmental agencies; our ability to maintain compliance with Nasdaq listing standards; our dependence on key members of management; and other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.


You should not rely on forward-looking statements as predictions of future events. Forward-looking statements in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update such statements to reflect actual results or changes in expectations, except as required by law.


[Financial Tables Follow]




ENDRA Life Sciences Inc.








Consolidated Balance Sheets













 



 






 






December 31,






 






 






December 31,






 









 






2025






 






 






2024






 








Assets






 






 






 






 






 






 








Current Assets






 






 






 






 






 






 








Cash






 






$






762,365






 






 






$






3,229,480






 








Prepaid expenses






 






 






205,604






 






 






 






204,185






 








Total Current Assets






 






 






967,969






 






 






 






3,433,665






 








Non-Current Assets






 






 






 






 






 






 






 






 








Fixed assets, net






 






 






42,516






 






 






 






69,281






 








Right of use assets






 






 






461,949






 






 






 






578,013






 








Prepaid expenses, long term






 






 






365,417






 






 






 






365,417






 








Digital Assets






 






 






2,009,960






 






 






 






-






 








Other assets






 






 






5,986






 






 






 






5,986






 








Total Assets






 






$






3,853,797






 






 






$






4,452,362






 








Liabilities and Stockholders’ Equity






 






 






 






 






 






 






 






 








Current Liabilities






 






 






 






 






 






 






 






 








Accounts payable and accrued liabilities






 






$






621,578






 






 






$






508,293






 








Lease liabilities, current portion






 






 






129,378






 






 






 






96,937






 








Total Current Liabilities






 






 






750,956






 






 






 






605,230






 








 






 






 






 






 






 






 






 






 








Long Term Debt






 






 






 






 






 






 






 






 








Lease liabilities






 






 






362,974






 






 






 






487,482






 








Warrant Liability






 






 






479,747






 






 






 






799,284






 








Total Long Term Debt






 






 






842,721






 






 






 






1,286,766






 








Total Liabilities






 






 






1,593,677






 






 






 






1,891,996






 








Commitments and Contingencies






 






 






-






 






 






 






-






 








 






 






 






 






 






 






 






 






 








Stockholders’ Equity






 






 






 






 






 






 






 






 








Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 17.488 and 17.488 shares issued and outstanding, respectively






 






 






-






 






 






 






-






 








Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; no shares issued and outstanding






 






 






-






 






 






 






-






 








Series C Preferred Stock, $0.0001 par value; 100,000 shares authorized; no shares issued and outstanding






 






 






-






 






 






 






-






 








Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 1,176,477 and 536,908 shares issued and outstanding, respectively






 






 






116






 






 






 






53






 








Additional paid in capital






 






 






112,725,513






 






 






 






105,998,412






 








Stock payable






 






 






-






 






 






 






-






 








Accumulated deficit






 






 






(110,465,509






)






 






 






(103,438,099






)








Total Stockholders’ Equity






 






 






2,260,120






 






 






 






2,560,366






 








Total Liabilities and Stockholders’ Equity






 






$






3,853,797






 






 






$






4,452,362






 









ENDRA Life Sciences Inc.








Consolidated Statements of Operations













 



 






 






Year Ended






 






 






Year Ended






 








 






 






December 31,






 






 






December 31,






 









 






2025






 






 






2024






 








Operating Expenses






 






 






 






 






 






 






 






 








Research and development






 






$






1,849,996






 






 






$






3,190,293






 








Sales and marketing






 






 






189,470






 






 






 






571,040






 








General and administrative






 






 






3,723,635






 






 






 






7,055,814






 








Total operating expenses






 






 






5,763,101






 






 






 






10,817,147






 








 






 






 






 






 






 






 






 






 








Operating loss






 






 






(5,763,101






)






 






 






(10,817,147






)








 






 






 






 






 






 






 






 






 








Other (expenses) income






 






 






 






 






 






 






 






 








Other income






 






 






71,224






 






 






 






108,484






 








Digital asset staking compensation






 






 






5,121






 






 






 






-






 








Change in fair value of digital assets






 






 






(995,161






)






 






 






-






 








Warrant expense






 






 






(665,030






)






 






 






(7,323,685






)








Changes in fair value of warrant liability






 






 






319,537






 






 






 






3,447,737






 








Gain on settlement of warrant exercise






 






 






-






 






 






 






3,076,664






 








Total other expenses






 






 






(1,264,309






)






 






 






(690,800






)








 






 






 






 






 






 






 






 






 








Loss from operations before income taxes






 






 






(7,027,410






)






 






 






(11,507,947






)








 






 






 






 






 






 






 






 






 








Provision for income taxes






 






 






-






 






 






 






-






 








 






 






 






 






 






 






 






 






 








Net Loss






 






$






(7,027,410






)






 






$






(11,507,947






)








 






 






 






 






 






 






 






 






 








Net loss per share – basic and diluted






 






$






(8.93






)






 






$






(56.94






)








 






 






 






 






 






 






 






 






 








Weighted average common shares – basic and diluted






 






 






787,020






 






 






 






202,106






 







 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260331142790/en/
Company Contact:

Investor Relations

investors@endrainc.com

www.endrainc.com


Investor Relations Contact:

Yvonne Briggs

Alliance Advisors IR

(310) 691-7100

ybriggs@allianceadvisors.com


Original: ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

NDRA.................................https://stockcharts.com/sc3/ui/?s=NDRA&p=W&b=5&g=0&id=p86431144783

$NDRA ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

https://www.businesswire.com/news/home/20260325586453/en/ENDRA-Life-Sciences-Initiates-Review-of-Strategic-Alternatives-to-Maximize-Shareholder-Value

Board to evaluate a range of alternatives while continuing to support core business priorities

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that its Board of Directors has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value.

As a part of this process, the Board will evaluate a range of potential alternatives, including, but not limited to strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or sale or merger of the Company.

ENDRA has engaged Lucid Capital Management as its financial advisor and K&L Gates as its legal counsel in connection with this process.

“The Board and management are committed to identifying and evaluating opportunities that may maximize the shareholder value while building on the progress we’ve made advancing ENDRA’s strategic priorities,” said Alexander Tokman, Chief Executive Officer of ENDRA Life Sciences. “We believe this process will help us assess a range of options available to the Company and determine the most appropriate path forward for ENDRA and its shareholders.”

The Company will continue to execute on its strategic and operating initiatives during the review process. The Company has not set a timetable for completion of the process, and does not intend to comment further unless and until additional disclosure is appropriate or required by law.

🚨 $NDRA MRI ON HIGH ALERT 🚨💯🚀

Fresh heat — ENDRA Life Sciences' TAEUS® Liver Device just dropped HIGH-LEVEL CONSISTENCY results: ICC of 0.89, SEM of 3.3% — delivering MRI-level precision for liver fat detection right at the point of care! 🔥

This non-invasive beast is crushing it for MASLD/MASH (liver disease affecting BILLIONS globally) — matching MRI-PDFF at key trial thresholds, no radiation, cheaper/faster than MRI!

✅ Recent clinical study: rock-solid repeatability
✅ Positioning for massive pharma trials & adoption
✅ Nano ~$3.8-4M market cap at ~$3.30/share + low float = extreme volatility setup
✅ Biotech runners explode on medtech validation like this

Real data catalyst in a microcap med device play — liver fat monitoring is a multi-billion unmet need!'

Who's loading $NDRA before the next leg up? 👀

DYOR | 🚨StockOnHighAlert🚀

$NDRA on High Alert -ENDRA Life Sciences (NASDAQ: NDRA) is advancing its TAEUS® liver device to detect liver fat, targeting a 250-subject clinical trial for FDA De Novo submission by year-end 2025. The company reported Q2 2025 results with reduced operating expenses.
Recent studies indicate high-level consistency, showing MRI-level results in assessing metabolic liver fat.

https://seekingalpha.com/pr/20415181-endra-s-taeus-liver-device-demonstrates-high-level-consistency-in-clinical-study-delivering via
@SeekingAlpha @Nasdaq

$NDRA TAEUS Device Achieves MRI-Level Liver Imaging Precision

The results are favorable in the context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition estimated to impact around 30% of the global adult population. The data support the device’s potential utility as a dependable point-of-care tool for disease assessment and management.

https://finance.yahoo.com/news/ndras-taeus-device-achieves-mri-151500079.html

$NDRA A new era for ultrasound
Our insight was simple: ultrasound can do much more than anyone realized. By using energy to stimulate tissue in concert with ultrasound, we can see whole new dimensions.

https://endrainc.com/about

$NDRA ENDRA Life Sciences NDRA recently announced positive findings from a clinical study assessing the measurement consistency of its TAEUS Liver device. The evaluation demonstrated strong intra-operator repeatability and inter-operator reproducibility, underscoring the platform’s reliability for longitudinal monitoring of Steatotic Liver Disease (SLD).

The results are favorable in the context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition estimated to impact around 30% of the global adult population. The data support the device’s potential utility as a dependable point-of-care tool for disease assessment and management.

Validating Measurement Reliability in MASLD Monitoring
The clinical study evaluated 14 subjects under real-world conditions, with independent operators performing multiple scans to assess system performance. A total of 56 measurements were analyzed using Gage Repeatability and Reproducibility (R&R) methodology, which determines how much observed variability stems from the device itself versus actual biological differences.

TAEUS Liver achieved an Intraclass Correlation Coefficient (ICC) of 0.89 and a Standard Error of Measurement (SEM) of 3.3%, placing performance within the “Good to Excellent” reliability range. These metrics are important in MASLD, where detecting small, incremental changes in liver fat is essential for treatment monitoring and clinical decision-making.

Bridging the Gap Between MRI Precision and Accessibility
While MRI-PDFF remains the gold standard for liver fat quantification, its high cost, limited availability and infrastructure requirements restrict widespread use — particularly for frequent monitoring. NDRA’s TAEUS platform aims to bridge this gap by delivering MRI-comparable quantitative assessment in a more accessible, ultrasound-based format deployable at the point of care.

TAEUS’ performance contrasts with conventional ultrasound techniques, which are often limited by operator dependency and subjective interpretation. ENDRA’s thermoacoustic biomarker imaging approach is designed to reduce variability and standardize liver fat assessment, addressing a longstanding limitation in non-invasive liver diagnostics.

Strategic and Market Implications
The data strengthen NDRA’s regulatory and commercial outlook, as consistent measurements are essential for diagnostic approval and treatment monitoring. For clinicians, a reliable point-of-care tool could support earlier intervention and frequent follow-up, while offering a cost-effective option for patient screening.


https://finance.yahoo.com/news/ndras-taeus-device-achieves-mri-151500079.html

$NDRA announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately 30% of adults worldwide.

🚨 $NDRA BIOTECH IMAGING ALERT – TAEUS LIVER DEVICE HITS MRI-LEVEL PRECISION IN STUDY! 🔥


ENDRA Life Sciences ($NDRA) DROPPING strong data: TAEUS® Liver device nailed high consistency in clinical study—MRI-level results at point-of-care for liver fat quantification (Pearson r=0.89, avg error ~3%, >90% within 5% margin)!
Key for MASLD/MASH detection + GLP-1 therapy monitoring—non-invasive, affordable alternative to pricey MRI scans.

Pivotal study path + FDA engagement planned 2026. Micro-cap beast (~$3.36–$3.43 hold after dips, volume building from $2.90 lows, analyst Strong Buy targets $30+ upside)! Chart teasing rebound in hot medical imaging/biotech narrative.
Undervalued execution play—FOMO on clinical wins!

Who's loading $NDRA dips here? Drop your entry or target below 👇💰

$4+ rebound quick? Or $10–$30+ on pivotal/FDA momentum?

Full PR (Feb 26!): https://www.businesswire.com/news/home/20260226198097/en/ENDRA%E2%80%99s-TAEUS%C2%AE-Liver-Device-Demonstrates-High-Level-Consistency-in-Clinical-Study-Delivering-MRI-Level-Results-at-the-Point-of-Patient-Care

#NDRA #Biotech #MedicalImaging #MASLD #PennyStocks #Nasdaq #Altseason

$NDRA ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

https://www.businesswire.com/news/home/20260226198097/en/ENDRAs-TAEUS-Liver-Device-Demonstrates-High-Level-Consistency-in-Clinical-Study-Delivering-MRI-Level-Results-at-the-Point-of-Patient-Care

Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately 30% of adults worldwide.

The study involved 14 subjects with independent operators performing several measurements each to assess the platform's performance in real-world clinical conditions. A total of 56 unique measurements were tabulated to generate comprehensive Gage Repeatability and Reproducibility (R&R) results. This methodology quantifies how much observed measurement variability comes from the measurement system itself rather than true patient-to-patient differences, a critical factor for regulatory validation and clinical decision-making around diagnostic and treatment thresholds.

TAEUS Liver achieved an ICC of 0.89 with an SEM of 3.3%, which is considered in the "Good to Excellent" performance range. These results demonstrate the device’s high reliability regardless of the clinician performing the scan and consistent repeatability when a single user performs back-to-back measurements.

"While MRI-PDFF remains the gold standard for liver fat quantification, its high cost and limited availability create significant barriers for the more than two billion people afflicted by MASLD," stated Alexander Tokman, Chief Executive Officer of ENDRA Life Sciences. "These new performance data showing a 3.3% SEM and a 0.89 ICC strongly support our belief that TAEUS can deliver consistent results similar to an MRI, but at the point of patient care and at a much lower cost. This addresses a critical need for clinicians and pharmaceutical companies that require a diagnostic tool to monitor treatment frequently and affordably."

The TAEUS system's performance also contrasts sharply with traditional ultrasound techniques, which suffer from high inter-observer variability and subjective interpretations. These study results support TAEUS’s objective to deliver a standardized, accurate and repeatable liver fat test for the growing population affected by MASLD. TAEUS could be deployed in routine clinical practice to address large, underserved populations and could potentially be utilized by pharmaceutical companies for patient recruitment and follow-up in clinical trials. As new metabolic therapies enter the market, the ability to detect small, incremental changes in liver fat without the cost burden of repeated MRI scans becomes increasingly important. ENDRA’s innovative approach with TAEUS seamlessly combines the precision traditionally associated with expensive imaging modalities with the practical deployment advantages of ultrasound-based systems.

ENDRA Life Sciences (NASDAQ: $NDRA ): A Dual-Engine Growth Story Alongside $KNRX, $BATL, $TALK, $DNN, $VZLA in Focus

https://thestreetreports.com/endra-life-sciences-nasdaq-ndra-a-dual-engine-growth-story-alongside-knrx-batl-talk-dnn-vzla-in-focus/

In a market searching for asymmetric upside, ENDRA Life Sciences (NASDAQ: NDRA) is quietly building one of the more compelling dual-engine growth narratives in the small-cap space. The company sits at the intersection of two powerful trends: breakthrough liver imaging technology and next-generation treasury strategy exposure to high-momentum digital assets like HYPE.

Alongside ENDRA Life Sciences (NASDAQ: NDRA), other small caps active in early trading include KNOREX Ltd. (NYSE: KNRX), Battalion Oil (NYSE: BATL), Talkspace (NASDAQ: TALK), Vizsla Silver (NYSE: VZLA), and Denison Mines (NYSE: DNN).

Most investors know ENDRA for TAEUS® (Thermo-Acoustic Enhanced UltraSound) — a point-of-care imaging system designed to quantify liver fat in real time. But what many may not fully appreciate is how rapidly the addressable market is expanding. Steatotic liver disease (SLD) and MASH affect more than 2 billion people globally, and the explosion of GLP-1 therapies, projected to exceed $100 billion annually, is dramatically increasing demand for non-invasive liver monitoring.

If TAEUS® secures broader clinical adoption or pharmaceutical trial integration, the upside could be substantial. MRI-PDFF remains the gold standard but is expensive and impractical for routine monitoring. A scalable, lower-cost alternative with validated clinical alignment represents a major disruption opportunity.

At the same time, ENDRA has implemented a forward-leaning treasury strategy that includes exposure to digital assets such as HYPE, which recently surged more than 50% amid rising platform adoption and trading activity. While ENDRA is not a crypto company, its balance-sheet positioning provides potential financial optionality beyond its clinical pipeline.

For investors, NDRA offers:

First-mover medical technology targeting a multi-billion-dollar health crisis
GLP-1-driven demand tailwinds
Clinical validation momentum
Balance-sheet optionality tied to digital asset strength
Reduced reliance on pure dilution-driven financing

Small caps that combine disruptive healthcare innovation with intelligent capital strategy are rare. If both engines—clinical execution and treasury performance—continue to advance, NDRA could transition from overlooked to re-rated quickly.

In markets where capital flows toward differentiated stories, ENDRA Life Sciences may be one of the more under-the-radar setups heading into the next phase of growth.

ndra.....................................................OUT

ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial UseDecember 04 2025 - 8:00AM
Business Wirehttps://twitter.com/sharehttp://www.facebook.com/sharer.php?s=100&p[url]=https%3A%2F%2Finvestorshub.advfn.com%2Fstock-market%2FNASDAQ%2Fendra-life-sciences-NDRA%2Fstock-news%2F97377638%2Fendra-s-taeus-liver-matches-mri-pdff-performanceFeasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoringENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS’ thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%.These thresholds separate mild, moderate and severe disease, are widely used to make clinical therapy decisions in routine practice and are important for enrolling patients in clinical trials. The high accuracy of TAEUS at these specific points strengthens its potential as a practical, low-cost tool for the booming MASLD/MASH and obesity drug development landscape.“Drug developers and payors need to know if a patient is above or below the specific thresholds that trigger costly therapies, reimbursement of those therapies or trial enrollment,” said Alexander Tokman, CEO of ENDRA Life Sciences. “Our data show TAEUS tracks MRI-PDFF closely across the full SLD spectrum, including the critical 12-22% range. Additionally, at the 8% LFF threshold used for Rezdiffra™ reimbursement determination, TAEUS delivered a high PPV as well.”In the recently completed feasibility study of 40 subjects with BMI ranging from 21 to 47, ENDRA evaluated the performance of its TAFF biomarker test against MRI-PDFF at decision thresholds that segment patients from mild to moderate-to-severe steatosis.TAEUS Key Performance Data vs. MRI-PDFFThe high Positive Predictive Value (PPV) demonstrates TAEUS’ potential to reliably identify patients above treatment thresholds, which is essential for trial inclusion and therapy escalation, while the high Negative Predictive Value (NPV) supports its use to rule out patients who fall outside of these thresholds. Accuracy reflects how well a diagnostic test correctly identifies the presence or absence of a disease compared to a gold standard for all subjects.Addressing a Major Cost in Drug DevelopmentWith 50+ MASLD/MASH and 250+ GLP-1 trials ongoing, MRI-PDFF is a standard, but costly tool for screening and monitoring, with exams often exceeding $2,500 each. This high-cost limits frequent monitoring and makes large, long-term trials prohibitively expensive.TAEUS is designed to disrupt this model and make liver fat quantification far more accessible by offering a point-of-care imaging solution at an anticipated cost of less than $200 (or less than 8% the cost of an MRI-PDFF exam) and the ability to perform frequent, longitudinal monitoring (e.g., every 8 weeks) to capture rapid drug-induced changes in LFF, which is impractical with MRI.Unlocking Strategic ValueThe feasibility study results de-risk several potential value-creating pathways for ENDRA:“If TAEUS can shift even a fraction of trial imaging from MRI-PDFF to a point-of-care modality with comparable performance, the cost savings to large pharma on a per-trial basis could be significant. We are focused on opportunities where modest investments in additional clinical and technical work can unlock disproportionate commercial and partnering leverage,” concluded Mr. Tokman. “These threshold-based data are a pivotal step in demonstrating TAEUS's utility in real-world clinical and economic decision-making.”Next StepsAbout ENDRA Life Sciences Inc.ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section of our website, www.endrainc.com.

$8

7.12

6.89 quick scalp

$6.70

$5.80

NDRA.........................................................a/h

NDRA.................................https://stockcharts.com/sc3/ui/?s=NDRA&p=W&b=5&g=0&id=p86431144783

$NDRA ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA

https://www.businesswire.com/news/home/20251113934707/en/ENDRA-Life-Sciences-Commences-Staking-of-HYPE-Digital-Asset-Holdings-Reinforcing-Long-Term-Strategy-with-Anchorage-Digital-and-ARCA

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today announced a significant step in its digital asset strategy with the commencement of staking its holdings of HYPE, the native token of the Hyperliquid ecosystem.

This strategic move, guided by ARCA Investment Management, LLC, and secured by Anchorage Digital, is designed to maximize the utility and return of the Company's HYPE treasury while actively contributing to the security and decentralization of the underlying blockchain network. Following the initial investment announced on October 23, 2025, ENDRA has successfully deployed its HYPE position into a secure, institutional-grade staking solution.

“Commencing our HYPE staking program is an essential evolution of our digital asset strategy,” said Alexander Tokman, Chief Executive Officer of ENDRA. “By partnering with industry leaders ARCA and Anchorage Digital, we are not just purchasing digital assets – we are putting capital to work in a productive, reward generating way, all within a robust and compliant institutional framework.”

Key benefits of the staking initiative include the following:

Reward Generation: Staking its HYPE assets enables ENDRA to generate consistent network incentives, which is expected to enhance shareholder value over the long term. This provides measurable asset compensation.
Network Security & Support: By participating in the staking mechanism, ENDRA is actively securing the Hyperliquid network, aligning its corporate interests with the health and stability of the digital asset ecosystem.
Strategic Participation: Staking provides ENDRA with enhanced access and optionality within the broader Hyperliquid ecosystem, including potential future governance rights and participation in decentralized finance (“DeFi”) opportunities.

This fundamental, bottoms-up approach to selecting assets like HYPE offers ENDRA the ability to earn compensation while diversifying its balance sheet assets. ARCA Investment Management’s role is to combine crypto-native expertise with traditional risk management to deliver disciplined, transparent solutions across market cycles. This staking initiative is an example of strategic success in the DeFi space.

Institutional participation in digital asset incentive opportunities requires the highest standards of security and regulatory compliance. Anchorage Digital Bank, the only federally chartered and regulated digital asset provider, delivers institutional-grade custody and integrated staking services that enable ENDRA to engage prudently with this asset class.

ENDRA will continue to monitor the digital asset landscape for opportunities that align with its disciplined, growth-focused treasury management strategy.

NDRA.................................https://stockcharts.com/sc3/ui/?s=NDRA&p=W&b=5&g=0&id=p86431144783

NDRA...$4.08...🥳... https://schrts.co/bZKTdRBa ...Float posted on Finiz under 1 Million...Bidding $3.75/$4.00 range...Previous Alert ran from $3 range to $11 range...

Thank you...🥳

NDRA — what a textbook micro-float runner. 👏
From $3.61 to $10.50… one of the cleanest trades we’ve seen in a while.

Major props to Georgie18 for calling this one super early — your $3.61 alert was dead-on and gave everyone here a real chance to ride it up. That kind of timing deserves real recognition.

This move checked all the boxes: micro float, volume surge, and momentum continuation. These are the trades we wait for. Let’s keep this energy going and stay sharp for the next setup — I’ve got a couple on radar for next week that show a similar early structure 👀

PROK in at $1.30 and SBET $13.33. Both are on fire today.

Anyone else lock in some gains on NDRA?

NDRA...$10.50...🥳...All out from $3.30/$3.60...

georgie18

Member Level
Re: georgie18 post# 1310

Tuesday, July 08, 2025 7:52:26 AM

Post#
1311
of 1311
NDRA...$9.72...🥳...Off my $3.61 Alert...

georgie18

Member Level
Re: georgie18 post# 395120

Tuesday, July 08, 2025 7:34:51 AM

Post#
395134
of 395140
NDRA $8.73...🥳...Another Breauty Runner...

georgie18

Member Level
Re: georgie18 post# 1306

Monday, July 07, 2025 4:37:09 PM

Post#
1308
of 1309
NDRA...$5.68...🥳...Beauty A/H move...Off my $3.61 Alert...

georgie18

Member Level
Re: georgie18 post# 392920

Monday, May 12, 2025 9:38:07 AM

Post#
393214
of 395119
NDRA...$3.37...Took sdome $3.30s on the dip...🥳

georgie18

Member Level
Re: georgie18 post# 1292

Friday, May 02, 2025 8:13:24 AM

Post#
1303
of 1305
NDRA...$7.00...🥳...Still holding 25%...Took profit on the rest...

georgie18

Member Level
Re: georgie18 post# 392845

Wednesday, April 30, 2025 9:35:39 AM

Post#
392851
of 392919
NDRA...$6.66...🥳...Took another 25% off the table...75% out from $3.60 range...

georgie18

Member Level
Re: georgie18 post# 1286

Tuesday, April 29, 2025 5:08:51 PM

Post#
1290
of 1291
NDRA...$6.01...Off my $3.61 Alert...🥳...Took 1/2 off the table...

georgie18

Member Level
Re: georgie18 post# 392826

Tuesday, April 29, 2025 2:12:07 PM

Post#
392839
of 392844
NDRA...$5.55...Hit $6 HOD...Off my $3.61 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 1283

Tuesday, April 29, 2025 12:38:43 PM

Post#
1284
of 1285
NDRA...$5.33...🥳...Micro Float can run hard from here...im,o...we shall see...

georgie18

Member Level
Re: georgie18 post# 392820

Tuesday, April 29, 2025 12:31:21 PM

Post#
392823
of 392824
NDRA...$5...There's the $5 Break I was looking for...🥳

georgie18

Member Level
Re: georgie18 post# 1280

Tuesday, April 29, 2025 12:12:05 PM

Post#
1282
of 1282
NDRA...$4.65...Off my $3.61 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 392600

Monday, April 28, 2025 3:41:55 PM

Post#
392779
of 392819
NDRA...$4.12...🥳...Off my $3.61 Alert...

georgie18

Member Level
Re: None

Wednesday, April 23, 2025 10:36:50 AM

Post#
1277
of 1279
NDRA...$3.61...🥳...Looking for $5 plus here...

NDRA...$9.72...🥳...Off my $3.61 Alert...

georgie18

Member Level
Re: georgie18 post# 395120

Tuesday, July 08, 2025 7:34:51 AM

Post#
395134
of 395140
NDRA $8.73...🥳...Another Breauty Runner...

georgie18

Member Level
Re: georgie18 post# 1306

Monday, July 07, 2025 4:37:09 PM

Post#
1308
of 1309
NDRA...$5.68...🥳...Beauty A/H move...Off my $3.61 Alert...

georgie18

Member Level
Re: georgie18 post# 392920

Monday, May 12, 2025 9:38:07 AM

Post#
393214
of 395119
NDRA...$3.37...Took sdome $3.30s on the dip...🥳

georgie18

Member Level
Re: georgie18 post# 1292

Friday, May 02, 2025 8:13:24 AM

Post#
1303
of 1305
NDRA...$7.00...🥳...Still holding 25%...Took profit on the rest...

georgie18

Member Level
Re: georgie18 post# 392845

Wednesday, April 30, 2025 9:35:39 AM

Post#
392851
of 392919
NDRA...$6.66...🥳...Took another 25% off the table...75% out from $3.60 range...

georgie18

Member Level
Re: georgie18 post# 1286

Tuesday, April 29, 2025 5:08:51 PM

Post#
1290
of 1291
NDRA...$6.01...Off my $3.61 Alert...🥳...Took 1/2 off the table...

georgie18

Member Level
Re: georgie18 post# 392826

Tuesday, April 29, 2025 2:12:07 PM

Post#
392839
of 392844
NDRA...$5.55...Hit $6 HOD...Off my $3.61 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 1283

Tuesday, April 29, 2025 12:38:43 PM

Post#
1284
of 1285
NDRA...$5.33...🥳...Micro Float can run hard from here...im,o...we shall see...

georgie18

Member Level
Re: georgie18 post# 392820

Tuesday, April 29, 2025 12:31:21 PM

Post#
392823
of 392824
NDRA...$5...There's the $5 Break I was looking for...🥳

georgie18

Member Level
Re: georgie18 post# 1280

Tuesday, April 29, 2025 12:12:05 PM

Post#
1282
of 1282
NDRA...$4.65...Off my $3.61 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 392600

Monday, April 28, 2025 3:41:55 PM

Post#
392779
of 392819
NDRA...$4.12...🥳...Off my $3.61 Alert...

georgie18

Member Level
Re: None

Wednesday, April 23, 2025 10:36:50 AM

Post#
1277
of 1279
NDRA...$3.61...🥳...Looking for $5 plus here...

NDRA $8.73...🥳...Another Breauty Runner...

georgie18

Member Level
Re: georgie18 post# 1306

Monday, July 07, 2025 4:37:09 PM

Post#
1308
of 1309
NDRA...$5.68...🥳...Beauty A/H move...Off my $3.61 Alert...

georgie18

Member Level
Re: georgie18 post# 392920

Monday, May 12, 2025 9:38:07 AM

Post#
393214
of 395119
NDRA...$3.37...Took sdome $3.30s on the dip...🥳

georgie18

Member Level
Re: georgie18 post# 1292

Friday, May 02, 2025 8:13:24 AM

Post#
1303
of 1305
NDRA...$7.00...🥳...Still holding 25%...Took profit on the rest...

georgie18

Member Level
Re: georgie18 post# 392845

Wednesday, April 30, 2025 9:35:39 AM

Post#
392851
of 392919
NDRA...$6.66...🥳...Took another 25% off the table...75% out from $3.60 range...

georgie18

Member Level
Re: georgie18 post# 1286

Tuesday, April 29, 2025 5:08:51 PM

Post#
1290
of 1291
NDRA...$6.01...Off my $3.61 Alert...🥳...Took 1/2 off the table...

georgie18

Member Level
Re: georgie18 post# 392826

Tuesday, April 29, 2025 2:12:07 PM

Post#
392839
of 392844
NDRA...$5.55...Hit $6 HOD...Off my $3.61 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 1283

Tuesday, April 29, 2025 12:38:43 PM

Post#
1284
of 1285
NDRA...$5.33...🥳...Micro Float can run hard from here...im,o...we shall see...

georgie18

Member Level
Re: georgie18 post# 392820

Tuesday, April 29, 2025 12:31:21 PM

Post#
392823
of 392824
NDRA...$5...There's the $5 Break I was looking for...🥳

georgie18

Member Level
Re: georgie18 post# 1280

Tuesday, April 29, 2025 12:12:05 PM

Post#
1282
of 1282
NDRA...$4.65...Off my $3.61 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 392600

Monday, April 28, 2025 3:41:55 PM

Post#
392779
of 392819
NDRA...$4.12...🥳...Off my $3.61 Alert...

georgie18

Member Level
Re: None

Wednesday, April 23, 2025 10:36:50 AM

Post#
1277
of 1279
NDRA...$3.61...🥳...Looking for $5 plus here...

Great start $NDRA 💹

NDRA...$5.68...🥳...Beauty A/H move...Off my $3.61 Alert...

georgie18

Member Level
Re: georgie18 post# 392920

Monday, May 12, 2025 9:38:07 AM

Post#
393214
of 395119
NDRA...$3.37...Took sdome $3.30s on the dip...🥳

georgie18

Member Level
Re: georgie18 post# 1292

Friday, May 02, 2025 8:13:24 AM

Post#
1303
of 1305
NDRA...$7.00...🥳...Still holding 25%...Took profit on the rest...

georgie18

Member Level
Re: georgie18 post# 392845

Wednesday, April 30, 2025 9:35:39 AM

Post#
392851
of 392919
NDRA...$6.66...🥳...Took another 25% off the table...75% out from $3.60 range...

georgie18

Member Level
Re: georgie18 post# 1286

Tuesday, April 29, 2025 5:08:51 PM

Post#
1290
of 1291
NDRA...$6.01...Off my $3.61 Alert...🥳...Took 1/2 off the table...

georgie18

Member Level
Re: georgie18 post# 392826

Tuesday, April 29, 2025 2:12:07 PM

Post#
392839
of 392844
NDRA...$5.55...Hit $6 HOD...Off my $3.61 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 1283

Tuesday, April 29, 2025 12:38:43 PM

Post#
1284
of 1285
NDRA...$5.33...🥳...Micro Float can run hard from here...im,o...we shall see...

georgie18

Member Level
Re: georgie18 post# 392820

Tuesday, April 29, 2025 12:31:21 PM

Post#
392823
of 392824
NDRA...$5...There's the $5 Break I was looking for...🥳

georgie18

Member Level
Re: georgie18 post# 1280

Tuesday, April 29, 2025 12:12:05 PM

Post#
1282
of 1282
NDRA...$4.65...Off my $3.61 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 392600

Monday, April 28, 2025 3:41:55 PM

Post#
392779
of 392819
NDRA...$4.12...🥳...Off my $3.61 Alert...

georgie18

Member Level
Re: None

Wednesday, April 23, 2025 10:36:50 AM

Post#
1277
of 1279
NDRA...$3.61...🥳...Looking for $5 plus here...

$NDRA 💹

NDRA...$3.37...Took sdome $3.30s on the dip...🥳

georgie18

Member Level
Re: georgie18 post# 1292

Friday, May 02, 2025 8:13:24 AM

Post#
1303
of 1305
NDRA...$7.00...🥳...Still holding 25%...Took profit on the rest...

georgie18

Member Level
Re: georgie18 post# 392845

Wednesday, April 30, 2025 9:35:39 AM

Post#
392851
of 392919
NDRA...$6.66...🥳...Took another 25% off the table...75% out from $3.60 range...

georgie18

Member Level
Re: georgie18 post# 1286

Tuesday, April 29, 2025 5:08:51 PM

Post#
1290
of 1291
NDRA...$6.01...Off my $3.61 Alert...🥳...Took 1/2 off the table...

georgie18

Member Level
Re: georgie18 post# 392826

Tuesday, April 29, 2025 2:12:07 PM

Post#
392839
of 392844
NDRA...$5.55...Hit $6 HOD...Off my $3.61 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 1283

Tuesday, April 29, 2025 12:38:43 PM

Post#
1284
of 1285
NDRA...$5.33...🥳...Micro Float can run hard from here...im,o...we shall see...

georgie18

Member Level
Re: georgie18 post# 392820

Tuesday, April 29, 2025 12:31:21 PM

Post#
392823
of 392824
NDRA...$5...There's the $5 Break I was looking for...🥳

georgie18

Member Level
Re: georgie18 post# 1280

Tuesday, April 29, 2025 12:12:05 PM

Post#
1282
of 1282
NDRA...$4.65...Off my $3.61 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 392600

Monday, April 28, 2025 3:41:55 PM

Post#
392779
of 392819
NDRA...$4.12...🥳...Off my $3.61 Alert...

georgie18

Member Level
Re: None

Wednesday, April 23, 2025 10:36:50 AM

Post#
1277
of 1279
NDRA...$3.61...🥳...Looking for $5 plus here...

NDRA, reports May 13 according to Seeking Alpha

My followers give a shit...and traders new to the game give a shit...🥳...and if you see today's dip it was a prudent trade...It's not bragging...it's giving information that some people pay attention too...and request...If you don't care then don't read it ...but do not think because you do not care that others do not care as well because they care and appreciate the information...Have a Great Weekend...

NDRA...$7.00...🥳...Still holding 25%...Took profit on the rest...

georgie18

Member Level
Re: georgie18 post# 392845

Wednesday, April 30, 2025 9:35:39 AM

Post#
392851
of 392919
NDRA...$6.66...🥳...Took another 25% off the table...75% out from $3.60 range...

georgie18

Member Level
Re: georgie18 post# 1286

Tuesday, April 29, 2025 5:08:51 PM

Post#
1290
of 1291
NDRA...$6.01...Off my $3.61 Alert...🥳...Took 1/2 off the table...

georgie18

Member Level
Re: georgie18 post# 392826

Tuesday, April 29, 2025 2:12:07 PM

Post#
392839
of 392844
NDRA...$5.55...Hit $6 HOD...Off my $3.61 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 1283

Tuesday, April 29, 2025 12:38:43 PM

Post#
1284
of 1285
NDRA...$5.33...🥳...Micro Float can run hard from here...im,o...we shall see...

georgie18

Member Level
Re: georgie18 post# 392820

Tuesday, April 29, 2025 12:31:21 PM

Post#
392823
of 392824
NDRA...$5...There's the $5 Break I was looking for...🥳

georgie18

Member Level
Re: georgie18 post# 1280

Tuesday, April 29, 2025 12:12:05 PM

Post#
1282
of 1282
NDRA...$4.65...Off my $3.61 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 392600

Monday, April 28, 2025 3:41:55 PM

Post#
392779
of 392819
NDRA...$4.12...🥳...Off my $3.61 Alert...

georgie18

Member Level
Re: None

Wednesday, April 23, 2025 10:36:50 AM

Post#
1277
of 1279
NDRA...$3.61...🥳...Looking for $5 plus here...

I’ll try similarly to stick to double from here.
Thanks, the device is revolutionary.
NDRA

They have one product that is trying to diagnose Liver Disease, with point of care, they only have 3 million in the bank, analyst price target is 50 dollars, as we know some analyst price targets most of the time doesn't even come to fruition, but what I do know is the market cap very small for almost 5 million market cap, this can easily fetch 10 million market cap, so my personal goal is a double from here, what happens after that I don't care, they will dilute at some point, how big is the question, maybe just enough to bring this tech to the market.

I agree scaling in is crucial since one can never obviously get it wright.
Also one can never for sure know what’s going to happen lol !!!!
NDRA

I also said buy slowly and it took 3 days to double. You should have least bought 500 shares on the first day and another 500 shares the second day before the run actually started.

Never go all in one ticker, always spread out, maybe your timing was off by a few days on $OMEX, the good day to make a move on $OMEX was Tuesday next week. Better luck next time.

Brag away my friend! You gave me this ticker on a silver platter a few days back when it was trading around 3.60. Only one you specifically named as one to put on my watch list as a buy now. I didn’t listen even though my gut instinct said now that looks like a good buy. I instead went against what I said I wasn’t going to do and took a position in OM-X and it’s been all down hill from there @!?#!@! Happy for you my friend you’ve been on a hot streak here of late. Got nothing but respect for you. I did tap out with a loss on OM-X today. Hopefully I’ll be able to make it up somewhere else.



dinogreeves Re: familyof5
Monday, 04/28/2025 8:57:55 AM

Thank family. Keep these on watchlist bro, I like you, you are good man. $NDRA, since my other ones have already taken off. Just buy slowly until news. Volume on OMEX after hours was very low, if it was 50 million plus volume, then I would have been somewhat concerned.

Who gives chit, whether someone sell half from $3.61 and another 25% in the 6 range. These low floaters can turn on a blink.

Lol…still here also.
NDRA

Still holding everything and yes I know, I don't need to brag what I sell and how much I sell, unless being asked.